Výsledky vyhledávání - Gil-Gil, Miguel

Upřesnit hledání
  1. 1
    Bevacizumab for the Treatment of Glioblastoma

    Bevacizumab for the Treatment of Glioblastoma Autor Gil-Gil, Miguel J., Mesia, Carlos, Rey, Montserrat, Bruna, Jordi

    Vydáno 2013
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer

    Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer Autor Vila, Mireia Margelí, Barco Berron, Sonia del, Gil-Gil, Miguel, Ochoa-Arnedo, Cristian, Vázquez, Rafael Villanueva

    Vydáno 2020
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  3. 3
    A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting

    A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive... Autor Sánchez‐Rovira, Pedro, Hirschberg, Angelica Lindén, Gil‐Gil, Miguel, Bermejo‐De Las Heras, Begoña, Nieto‐Magro, Concepción

    Vydáno 2020
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  4. 4
    The role of CDK4/6 inhibitors in early breast cancer

    The role of CDK4/6 inhibitors in early breast cancer Autor Gil-Gil, Miguel, Alba, Emilio, Gavilá, Joaquín, de la Haba-Rodríguez, Juan, Ciruelos, Eva, Tolosa, Pablo, Candini, Daniele, Llombart-Cussac, Antonio

    Vydáno 2021
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Cognitive and brain structural changes in long-term oligodendroglial tumor survivors

    Cognitive and brain structural changes in long-term oligodendroglial tumor survivors Autor Cayuela, Nuria, Jaramillo-Jiménez, Esteban, Càmara, Estela, Majós, Carles, Vidal, Noemi, Lucas, Anna, Gil-Gil, Miguel, Graus, Francesc, Bruna, Jordi, Simó, Marta

    Vydáno 2019
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab(†)

    Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab(†) Autor Balaña, Carmen, Estival, Anna, Pineda, Estela, Sepúlveda, Juan, Mesía, Carles, del Barco, Sonia, Gil-Gil, Miguel, Hardy, Max, Indacoechea, Alberto, Cardona, Andrés Felipe

    Vydáno 2017
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial

    Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroida... Autor Hirschberg, Angelica Lindén, Sánchez-Rovira, Pedro, Presa-Lorite, Jesús, Campos-Delgado, Miriam, Gil-Gil, Miguel, Lidbrink, Elisabet, Suárez-Almarza, Javier, Nieto-Magro, Concepción

    Vydáno 2020
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study

    Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study Autor Redondo, Andrés, Ramos Vázquez, Manuel, Manso, Luis, Gil Gil, Miguel J, Garau Llinas, Isabel, García-Garre, Elisa, Rodríguez, César A, Chacón, José Ignacio, López-Vivanco, Guillermo

    Vydáno 2018
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

    Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center Autor Sirvén, Milana Bergamino, Fernández-Ortega, Adela, Stradella, Agostina, Morilla, Idoia, Falo, Catalina, Vázquez, Silvia, Castany, Roser, Villanueva, Rafael, Recalde, Sabela, Pérez, Valentí Navarro, Gil-Gil, Miguel, Pernas, Sonia

    Vydáno 2019
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis

    Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis Autor Martínez-Aranda, Antonio, Hernández, Vanessa, Moreno, Ferran, Baixeras, Núria, Cuadras, Daniel, Urruticoechea, Ander, Gil-Gil, Miguel, Vidal, Noemí, Andreu, Xavier, Seguí, Miquel A., Ballester, Rosa, Castella, Eva, Sierra, Angels

    Vydáno 2017
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients

    Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients Autor Molina, David, Pérez-Beteta, Julián, Martínez-González, Alicia, Sepúlveda, Juan M., Peralta, Sergi, Gil-Gil, Miguel J., Reynes, Gaspar, Herrero, Ana, De Las Peñas, Ramón, Luque, Raquel, Capellades, Jaume, Balaña, Carmen, Pérez-García, Víctor M.

    Vydáno 2016
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients

    Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients Autor Estival, Anna, Sanz, Carolina, Ramirez, Jose-Luis, Velarde, Jose Maria, Domenech, Marta, Carrato, Cristina, de las Peñas, Ramón, Gil-Gil, Miguel, Sepúlveda, Juan, Armengol, Roser, Cardiel, Isaac, Berrocal, Alfonso, Luque, Raquel, Herrero, Ana, Balana, Carmen

    Vydáno 2019
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  13. 13
    PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

    PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution Autor Pernas, Sonia, Petit, Anna, Climent, Fina, Paré, Laia, Perez-Martin, J., Ventura, Luz, Bergamino, Milana, Galván, Patricia, Falo, Catalina, Morilla, Idoia, Fernandez-Ortega, Adela, Stradella, Agostina, Rey, Montse, Garcia-Tejedor, Amparo, Gil-Gil, Miguel, Prat, Aleix

    Vydáno 2019
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

    Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single... Autor Pernas, Sonia, Petit, Anna, Climent, Fina, Paré, Laia, Perez-Martin, J., Ventura, Luz, Bergamino, Milana, Galván, Patricia, Falo, Catalina, Morilla, Idoia, Fernandez-Ortega, Adela, Stradella, Agostina, Rey, Montse, Garcia-Tejedor, Amparo, Gil-Gil, Miguel, Prat, Aleix

    Vydáno 2019
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

    Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study Autor Rosenthal, Mark, Clement, Paul M, Campone, Mario, Gil-Gil, Miguel J, DeGroot, John, Chinot, Olivier, Idbaih, Ahmed, Gan, Hui, Raizer, Jeffrey, Wen, Patrick Yung, Pineda, Estela, Donnet, Valerie, Mills, David, El-Hashimy, Mona, Mason, Warren

    Vydáno 2020
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial

    Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial Autor Martínez-García, María, Velasco, Guillermo, Pineda, Estela, Gil-Gil, Miguel, Alameda, Francesc, Capellades, Jaume, Martín-Soberón, Mari Cruz, López-Valero, Israel, Tovar Ambel, Elena, Foro, Palmira, Taus, Álvaro, Arumi, Montserrat, Hernández-Laín, Aurelio, Sepúlveda-Sánchez, Juan Manuel

    Vydáno 2022
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

    Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Fina... Autor Gil-Gil, Miguel J., Bellet, Meritxell, Bergamino, Milana, Morales, Serafín, Barnadas, Agustí, Manso, Luís, Saura, Cristina, Fernández-Ortega, Adela, Garcia-Martinez, Elena, Martinez-Jañez, Noelia, Melé, Mireia, Villagrasa, Patricia, Celiz, Pamela, Perez Martin, X., Ciruelos, Eva, Pernas, Sonia

    Vydáno 2021
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

    Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification Autor Sepúlveda-Sánchez, Juan Manuel, Vaz, María Ángeles, Balañá, Carmen, Gil-Gil, Miguel, Reynés, Gaspar, Gallego, Óscar, Martínez-García, María, Vicente, Elena, Quindós, María, Luque, Raquel, Ramos, Ana, Ruano, Yolanda, Pérez-Segura, Pedro, Benavides, Manuel, Sánchez-Gómez, Pilar, Hernández-Laín, Aurelio

    Vydáno 2017
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Pseudoprogression as an adverse event of glioblastoma therapy

    Pseudoprogression as an adverse event of glioblastoma therapy Autor Balaña, Carmen, Capellades, Jaume, Pineda, Estela, Estival, Anna, Puig, Josep, Domenech, Sira, Verger, Eugenia, Pujol, Teresa, Martinez‐García, Maria, Oleaga, Laura, Velarde, JoseMaria, Mesia, Carlos, Fuentes, Rafael, Marruecos, Jordi, Del Barco, Sonia, Villà, Salvador, Carrato, Cristina, Gallego, Oscar, Gil‐Gil, Miguel, Craven‐Bartle, Jordi, Alameda, Francesc

    Vydáno 2017
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  20. 20
    A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

    A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma Autor Brandes, Alba A., Gil‐Gil, Miguel, Saran, Frank, Carpentier, Antoine F., Nowak, Anna K., Mason, Warren, Zagonel, Vittorina, Dubois, François, Finocchiaro, Gaetano, Fountzilas, George, Cernea, Dana Michaela, Chinot, Oliver, Anghel, Rodica, Ghiringhelli, Francois, Beauchesne, Patrick, Lombardi, Giuseppe, Franceschi, Enrico, Makrutzki, Martina, Mpofu, Chiedzo, Urban, Hans‐Joerg, Pichler, Josef

    Vydáno 2018
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: